UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 20-F/A
¨ Registration statement pursuant to Section 12(b) or (g)
of the Securities Exchange Act of 1934
or
x Annual report pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
FOR THE FISCAL YEAR ENDED NOVEMBER 30, 2013; or
¨ Transition report pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
or
¨ Shell company report pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of event requiring this shell company report:
For the transition period from to
Commission file number: 1-35203
THERATECHNOLOGIES INC.
(Exact name of registrant as specified in its charter)
Quebec
(Jurisdiction of incorporation or organization)
2310 Alfred-Nobel Blvd.
Montreal, Quebec, Canada, H4S 2B4
(Address of principal executive offices)
Luc Tanguay
Tel: (514) 336-7800
Fax: (514) 331-9691
2310 Alfred-Nobel Boulevard
Montreal, Quebec, Canada H4S 2B4
(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)
SECURITIES REGISTERED OR TO BE REGISTERED
PURSUANT TO SECTION 12(b) OF THE ACT:
Common Shares, no par value (Title of each class) | The Toronto Stock Exchange (Name of each exchange on which registered) |
SECURITIES REGISTERED OR TO BE REGISTERED
PURSUANT TO SECTION 12(g) OF THE ACT:
N/A
SECURITIES FOR WHICH THERE IS A REPORTING OBLIGATION
PURSUANT TO SECTION 15(d) OF THE ACT:
N/A
Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report.
61,010,603 Common Shares
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes¨ Nox
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes¨ Nox
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yesx No¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes¨ No¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):
¨ Large accelerated filer¨ Accelerated filerx Non-accelerated filer
Indicate by check mark which basis of accounting the registrant has used to prepare the statements included in this filing:
U.S. GAAP¨ International Financial Reporting Standards as issued by the International Accounting Standards Boardx Other¨
If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow. Item 17¨ Item 18¨ |
If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes¨ Nox
References in this Amendment No. 1 to Form 20-F to “Theratechnologies”, the “Company”, the “Corporation”, “we”, “our” and “us” or similar terms refer to Theratechnologies Inc. and its subsidiaries on a consolidated basis, unless otherwise indicated or unless the context requires otherwise.
Explanatory Note
This Amendment No. 1 (this “Amendment”) to our annual report on Form 20-F for the fiscal year ended November 30, 2013, filed on February 27, 2014 (the “Form 20-F”), is being filed solely to replace Exhibit 4.12 with the attached Exhibit 4.12 to reflect changes in the redacted portions of such exhibit in connection with our request for confidential treatment of portions of such exhibit. These changes in redactions were made in response to comments that we received from the Securities and Exchange Commission regarding our confidential treatment request. Except as described above, no other change has been made to the Form 20-F. The filing of this Amendment should not be understood to mean that any statements contained in the Form 20-F are true or complete as of any date subsequent to February 27, 2014.
1
SIGNATURES
The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.
THERATECHNOLOGIES INC. | ||||||
Date: April 7, 2014 | By: | /s/ Luc Tanguay | ||||
Name: Luc Tanguay | ||||||
President and Chief Executive Officer |
2
Exhibit Index
to Amendment No. 1 to Form 20-F
Exhibit | Description of Exhibit | |
4.12 | Master Service Agreement dated December 10, 2013 between Ventiv Commercial Services, LLC and Theratechnologies Inc. + |
+ | Confidential treatment has been requested with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC. |
3